Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

81.73 -2.45 (-2.91%)
Streaming Delayed Price Updated: 3:34 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Protagonist (PTGX) Earnings Call Transcript ↗
Protagonist (PTGX) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
What 7 Analyst Ratings Have To Say About Protagonist Therapeutics ↗
 
Via Benzinga
News headline image
Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million ↗
Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million 
Via The Motley Fool
Topics Energy
News headline image
Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million ↗
Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million 
Via The Motley Fool
BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In ↗
Via Stocktwits
News headline image
9 Analysts Assess Protagonist Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million ↗
Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
2 Top Dividend Kings Every Income Investor Should Own ↗
These companies pay durable and steadily rising dividends. 
Via The Motley Fool
Topics Bonds
News headline image
Johnson & Johnson's M&A Strategy Is the Real Story for Investors ↗
Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets. 
Via MarketBeat
News headline image
Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook ↗
Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes. 
Via Benzinga
News headline image
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print ↗
Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline. 
Via Stocktwits
Topics Government World Trade
News headline image
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch ↗
Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst. 
Via Benzinga
News headline image
FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy ↗
FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's overall benefit. 
Via Benzinga
News headline image
Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears ↗
U.S. markets were rattled on Friday after President Trump reignited trade tensions with China, triggering the sharpest sell-off since April. Tech and AI stocks led the decline, while gold and... 
Via Chartmill
Topics Artificial Intelligence Government World Trade
News headline image
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today ↗
The company could soon be swallowed by a very large peer -- which also happens to be a business partner. 
Via The Motley Fool
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report ↗
Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio. 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Friday? ↗
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
5 Analysts Assess Protagonist Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
Demystifying Protagonist Therapeutics: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials ↗
Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis. 
Via Benzinga
News headline image
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Protagonist Therapeutics ↗
 
Via Benzinga
News headline image
Protagonist (PTGX) Q2 Revenue Falls 26% ↗
Via The Motley Fool
News headline image
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? ↗
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
News headline image
PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) showing some interesting technicals. Here's why. ↗
Interesting Technical Analysis finding for PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX): Indications Suggest NASDAQ:PTGX Could Be on the Verge of a Breakout. 
Via Chartmill
News headline image
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study ↗
Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting. 
Via Benzinga
News headline image
Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study ↗
Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.